<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01988012</url>
  </required_header>
  <id_info>
    <org_study_id>ML28698</org_study_id>
    <nct_id>NCT01988012</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of RoActemra/Actemra in Patients With Rheumatoid Arthritis.</brief_title>
  <official_title>An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, single-arm study will evaluate the safety and efficacy of RoActemra/Actemra
      alone or concomitant with other antirheumatic drugs when administered as a single, weekly
      injection in patients with rheumatoid arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy: Patient-reported outcome of disease activity</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Change in disease activity, scored on CDAI/SDAI</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Proportion of patients in remission/with lowered disease score</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Reduction/discontinuation of parallel therapies.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life assessment</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Assessment of immunogenicity</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RoActemra/Actemra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab [RoActemra/Actemra!</intervention_name>
    <description>162 mg administered subcutaneously once a week</description>
    <arm_group_label>RoActemra/Actemra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;/= 18 years of age

          -  Patients with a diagnosis of active RA according to the revised (1987) ACR criteria
             on EULAR/ACR (2010) criteria

          -  Patients who were previously treated with:

          -  Three non-biologic DMARDs, and were not treated with any biologic agent; OR

          -  One biologic agent (alone or in combination with non-biologic DMARDs), and
             discontinued that agent for a reason

          -  Oral corticosteroids (&lt;/= 10 mg/day prednisone or equivalent), NSAIDs and
             non-biologic DMARDs are permitted if on a stable dose regimen for &gt;/= 4 weeks prior
             to Baseline

          -  Use of effective contraception throughout the study as defined by protocol; female
             patients of childbearing potential must not be pregnant

        Exclusion Criteria:

          -  Presence of serious, uncontrolled, clinically significant medical conditions

          -  History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic
             ulcerative lower GI disease that might predispose to perforation

          -  Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other
             infections

          -  Any infection requiring hospitalization or treatment with IV antibiotics within 4
             weeks of Screening or oral antibiotics within 2 weeks of Screening

          -  Clinically significant findings on lab tests and/or hepatitis B or C, or HIV
             screenings

          -  Active TB requiring treatments within the previous 3 years

          -  Evidence of active malignant disease, malignancies diagnosed within the previous 10
             years, or breast cancer diagnosed within the previous 20 years

          -  History of alcohol, drug, or chemical abuse within 1 year prior to Screening

          -  Neuropathies or other conditions that might interfere with pain evaluation

          -  Major surgery (including joint surgery) within 8 weeks prior to Screening or planned
             major surgery within 6 months following Baseline

          -  Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus,
             mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic
             involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's
             syndrome). Secondary Sj√∂gren's syndrome with RA is permitted

          -  Functional Class IV as defined by the ACR Classification of Functional Status
             in-Rheumatoid Arthritis (Appendix 2)

          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age
             of 16

          -  Prior history of current inflammatory joint disease other than RA

          -  Exposure to RoActemra/Actemra (either IV or SC) at any time prior to Baseline

          -  Treatment with any investigational agent within 4 weeks (or five half-lives of the
             investigational drug, whichever is longer) of Screening

          -  Previous treatment with any cell-depleting therapies, including investigational
             agents approved therapies, with alkylating agents such as chlorambucil, or with total
             lymphoid irradiation

          -  Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline

          -  Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML28698 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Yaacov</city>
        <zip>6093000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>34354</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49372</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramat Gan</city>
        <zip>52620-00</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
